Skip to main content
    V

    Veracyte Inc (VCYT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $24.01
    -0.32 (-1.32%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Veracyte Inc (VCYT) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Veracyte (VCYT) trades at 13.3x trailing earnings and 3.3x sales. Its P/S of 3.3x is below its 5-year median of 5.7x. Its forward P/E is 13.1x. The median P/E across 5 similar companies is 48.2x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 1.5% higher over the next year. Its free cash flow yield is 8.4%.

    MultipleValue
    P/E (trailing)13.3x
    Forward P/E13.1x
    Price to sales3.3x
    Price to book1.3x
    EV/EBITDA12.7x
    Price to FCF11.9x
    EV/FCF10.7x
    PEGN/A
    FCF yield8.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 44.1% below 5.9x and its P/B is 55.2% below 2.9x.

    MultipleCurrent5-year median10-year median
    P/S3.3x5.7x5.9x
    P/B1.3x1.8x2.9x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 3.1x in 2017 to 22.2x in 2020.

    Year endPriceP/EP/SP/B
    2025$42.1023.5x6.4x2.6x
    2024$39.6038.4x6.9x2.7x
    2023$27.51N/A5.5x1.9x
    2022$23.73N/A5.7x1.6x
    2021$41.20N/A12.8x2.7x
    2020$48.94N/A22.2x6.7x
    2019$27.92N/A10.7x5.7x
    2018$12.58N/A5.1x6.4x
    2017$6.53N/A3.1x6.0x
    2016$7.74N/A3.4x4.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VCYT

    What is VCYT's forward P/E ratio?

    Veracyte has a forward P/E ratio of 13.1x.

    Is VCYT stock overvalued?

    GNG's valuation label for VCYT is Undervalued. Its P/E of 13.3x compares with a median of 48.2x across 5 similar companies.

    What is VCYT's price to sales ratio?

    Veracyte has a price to sales ratio of 3.3x.